Maxcyte Inc Quick Ratio (MXCT) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Maxcyte inc   (NASDAQ: MXCT)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare

Maxcyte Inc 's Quick Ratio

MXCT's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 10.68 below Maxcyte Inc average.

Within Medical Laboratories industry 4 other companies have achieved higher Quick Ratio than Maxcyte Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 275 to 430.

Explain Quick Ratio?
How much Cash & cash equivalents MXCT´s has?
What are MXCT´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

MXCT Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change -3.44 % -22.86 % -28.73 % -11.52 % -10.09 %
Y / Y Cash & cash equivalent Change -16.49 % -22.72 % -33.3 % -31.27 % -19.56 %
Quick Ratio MRQ 10.68 12.09 9.7 7.15 12.35
MXCT's Total Ranking # 430 # 275 # 0 # 392 #
Seq. Current Liabilities Change 11.96 % -16.83 % -28.14 % 44.32 % -10.56 %
Seq. Cash & cash equivalent Change -1.09 % 3.7 % -2.54 % -16.46 % -8.47 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Medical Laboratories Industry # 5
Healthcare Sector # 151
Overall Market # 430


Quick Ratio Statistics
High Average Low
21.32 12.35 5.98
(Sep 30 2021)   (Dec 31 2020)




Financial Statements
Maxcyte Inc 's Current Liabilities $ 10 Millions Visit MXCT's Balance sheet
Maxcyte Inc 's Cash & cash equivalent $ 106 Millions Visit MXCT's Balance sheet
Source of MXCT's Sales Visit MXCT's Sales by Geography


Cumulative Maxcyte Inc 's Quick Ratio

MXCT's Quick Ratio for the trailling 12 Months

MXCT Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth -17.22 % -18.32 % -15.37 % -11.14 % -6.57 %
Y / Y Cash & cash equivalent TTM Growth -26.49 % -26.78 % -24 % -17.57 % -14.88 %
Quick Ratio TTM 9.54 9.94 10.05 10.21 10.75
Total Ranking TTM # 3917 # 2746 # 0 # 2574 #
Seq. Current Liabilities TTM Growth -0.79 % -5.56 % -8.33 % -3.61 % -2.11 %
Seq. Cash & cash equivalent TTM Growth -4.72 % -6.63 % -9.8 % -8.39 % -5.09 %

Quick ratio ranking by company, industry and sector >> Back to MXCT Financial Strength Comparisons >> Go to Compare MXCT Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in MXCT's Current Liabilities to $9.90 millions, cumulative Quick Ratio to 9.54 above the company average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Medical Laboratories industry 34 other companies have achieved higher Quick Ratio than Maxcyte Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 2746 to 3917.

Explain Quick Ratio?
How much Cash & cash equivalents MXCT´s has?
What are MXCT´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Medical Laboratories Industry # 35
Healthcare Sector # 890
Within the Market # 3917


trailing twelve months Quick Ratio Statistics
High Average Low
7.37 3.15 1.2
(Jun 30 2022)   (Mar 31 2026)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Medical Laboratories Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Aclarion Inc   15.50 $ 16.285  Millions$ 1.051  Millions
Miragen Therapeutics Inc   12.67 $ 981.530  Millions$ 77.484  Millions
Maxcyte inc   10.68 $ 105.690  Millions$ 9.895  Millions
Grail Inc   10.29 $ 859.755  Millions$ 83.542  Millions
Absci Corp  10.12 $ 201.142  Millions$ 19.878  Millions
Billiontoone Inc   9.85 $ 548.628  Millions$ 55.725  Millions
Celcuity Inc   8.68 $ 754.000  Millions$ 86.873  Millions
Veracyte Inc   7.76 $ 487.046  Millions$ 62.736  Millions
Personalis Inc   6.00 $ 278.411  Millions$ 46.385  Millions
Castle Biosciences Inc   4.72 $ 266.805  Millions$ 56.509  Millions
Bionexus Gene Lab Corp   4.33 $ 3.522  Millions$ 0.813  Millions
Caredx Inc   3.99 $ 373.636  Millions$ 93.698  Millions
Omniab Inc   3.78 $ 51.995  Millions$ 13.758  Millions
Fulgent Genetics Inc   3.58 $ 257.032  Millions$ 71.756  Millions
Guardant Health Inc   3.11 $ 1,053.469  Millions$ 338.962  Millions

Date modified: 2026-09-26T07:40:41+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.